KOSEN 한인과학기술자네트워크

Heart and Vascular Diseases Primary Sponsor: Department of Health and Human Services Deadline: 4/1/2001; 8/1/2001; 12/1/2001 KEYWORDS National Heart, Lung, and Blood Institute (NHLBI) The NHLBI plans, conducts and supports research, clinical trials and demonstrations relating to the causes, prevention, diagnosis and treatment of heart, blood vessel, lung, and blood diseases and sleep disorders. The NHLBI SBIR/STTR program fosters basic, applied, and clinical research on all product and service development related to the mission of the NHLBI. Research may be targeted to gender, race, or age subgroups. For more specific information about areas of interest to the NHLBI, please visit our home page at http://www.nhlbi.nih.gov Research topics of interest include, but are not limited to, research and development of the following: Heart and Vascular Diseases The Division of Heart and Vascular Diseases plans and directs the NHLBI's research grant, contract, and training programs in heart and vascular diseases. These programs encompass institute- and investigator-initiated basic research, targeted research, specialized centers and clinical trials. The DHVD maintains surveillance over developments in its program areas and assesses the national need for research on the causes, prevention, diagnosis, and treatment of cardiovascular disease. The DHVD ensures that effective new techniques, treatments and strategies resulting from medical research are transferred to the community through professional, patient, and public education programs in a timely manner. The Division has three major programs: the Heart Research Program, the Vascular Biology Research Program, and the Clinical & Molecular Medicine Program, in addition to a Research Training and Special Programs Group. 1. Heart Research Program. Supports basic, applied, and clinical research in cardiac diseases, from embryonic life to adulthood. 2. Vascular Biology Research Program. Supports research in atherosclerosis, hypertension, basic vascular biology and gene therapy for the prevention and/or treatment of vascular diseases. 3. Clinical & Molecular Medicine Program. Supports clinical, basic and engineering research on cardiovascular disease and health. Its scope includes genetic, genomic and proteomic research; engineering theory and practice applied to biology and medicine including therapeutic cardiovascular devices and diagnostic instrumentation; informatics and simulation; and cohort, case-control, and randomized clinical trials. A. Ambulatory monitoring (long term) of blood pressure. B. Angioscopes with increased flexibility and enhanced resolution. C. Animal models for assessing genetic determinants. D. Anti-hypertensive drugs from natural and synthetic sources. E. Biological, chemical, and mechanical sensors. F. Biologics. G. Biomaterials. H. Biomimetics. I. Biotechnologies. J Cholesterol measurement (total, HDL, and LDL) in fresh human serum, without matrix effects. K. Circulatory support systems. 1. Artificial heart. 2. Ventricular assistance. 3. Automatic control. 4. New animal models for in vivo testing. 5. Percutaneous and transcutaneous transmission of electrical energy. 6. Implantable rechargeable batteries and alternate power sources. L. Computerized modeling of hemodynamics in complex congenital heart disease. M. Cryopreservation of rat embryos for cardiovascular research. N. Development of new and improved antisense agents for the cardiovascular system focusing on the mode of introduction; the optimal length and specificity of the oligomer; non_specific interactions with other cellular components; and the potential toxic effects and the exact mechanism of the antisense oligomer. O. Development of phenotypic screening methods in the mouse for heart, lung, and blood diseases and sleep disorders. P. Diagnostic instrumentation for the mouse and rat. Q. Education and video systems. R. Functional tissue engineering. S. Gene and gene product relationship, structure, and function. T. Gene assessment and diagnostic technologies. U. Genomic applications and tools. V. Geographic sensing systems for high risk patients. W. Heart failure, early detection and treatment strategies. X. Informatics, modeling and simulation. Y. Intermediate phenotypes in hypertension. Z. Luminescent dyes to measure toxic metabolic intermediates in living cells in real time. AA. Mathematical and computer modeling of structure, function, and electrical activity of the normal and diseased heart. BB. Medical imaging systems. CC. Medical implants (heart valves, vascular grafts, stents, pacemakers, defibrillators, etc.). 1. Novel designs and materials. 2. Failure prediction/analysis. 3. Manufacturing. 4. Monitoring. 5. Preservation methods. 6. Quality assurance and quality control. 7. Reference biomaterials for evaluation of biocompatibility. 8. Reliability. 9. Biological response. DD. Molecular and gene imaging EE. Neuro-imaging in hypertension. FF. Noninvasive methods of detecting cardiac rejection, particularly in infants and young children. GG. Non-toxic and selective molecular cages for delivering short-lived vasoactive agents to the vasculature. HH. Nutrition. II. Precursors of preeclampsia, pregnancy-induced hypertension. JJ. Preservations methods for cardiovascular tissues or organs for use in transplantation and in research studies. KK. Pro- and anti-angiogenic and vasculogenic genes, proteins and drugs. LL. Proteomics. MM. Radiologic phantoms mimicking the human torso. NN. Magnetic resonance, x-ray, nuclear medicine. OO. Resuscitation-enabling technologies. PP. Training. QQ. Vaccines for the prevention or treatment of atherosclerosis. RR. Vascular and renal tubular fluid dynamics, non-invasive assessment. SS. Viral and non-viral vectors for gene therapy. For additional information on research topics, contact: Heart and Vascular Diseases Dr. Rosalie Dunn Division of Heart and Vascular Diseases 6701 Rockledge Drive, Room 9196 (301) 435-0505; Fax: (310) 480-1454 Email: rd39w@nih.gov Lung Diseases Dr. Robert Musson Division of Lung Diseases 6701 Rockledge Drive, Room 10108 Bethesda, MD 20892-7952 (301) 435-0222; Fax: (301) 480-3557 Email: rm65o@nih.gov Ms. Ann Rothgeb Division of Lung Diseases 6701 Rockledge Drive, Room 10114 Bethesda, MD 20892-7952 (301) 435-0202; Fax: (301) 480-3557 Email: ar31t@nih.gov Blood Diseases and Resources Ms. Susan E. Pucie Division of Blood Diseases and Blood Resources 6701 Rockledge Drive, Room 10166 Bethesda, MD 20892-7950 (301) 435-0079; Fax: (301) 480-0867 Email: sp34j@nih.gov Epidemiology and Clinical Applications Dr. Thomas Blaszkowski Division of Epidemiology and Clinical Applications 6701 Rockledge Drive, Room 8106 Bethesda, MD 20892-7938 (301) 496-1841; Fax: (301) 496-0075 Email: tb33i@nih.gov For administrative and business management questions, contact: Mr. Ed Donohue National Heart, Lung, and Blood Institute 6701 Rockledge Drive, Room 7160 Bethesda, MD 20892-7926 (301) 435-0144; Fax: (301) 480-3310 Email: ed25b@nih.gov NOTE: The Solicitations listed on this site are partial copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should always use the suggested links on our reference pages. These will take you directly to the appropriate agency information where you can read the official version of the solicitation you are interested in. The official link for this page is: http://grants.nih.gov/grants/funding/sbir.htm. Solicitation closing dates are: April 1, August 1, and December 1, 2001.